







### New logical framework approach, including indicators

Antonio Petrini

Coordinator
GF-TADs Global Secretariat










#### **Reason for the revision**

ISSUES	SOLUTIONS
expected results of GF-TADs not clear or harmonized by regions	Refine the results statements and embed them in a logical framework showing the hierarchy of results
Indicators not meaningful and too burdensome to report upon	Standardize and streamline reporting templates/processes across regions
Reporting not standardized across regions (for a global overview of progress	Refine indicators at all levels focusing on Outcome and Outputs and harmonizing diseases & regions



#### **Revision process**



We started consolidating regional action plans and revising the results Framework.

GF-TADs Management Committee (MC) endorsed the draft framework and the revision principles.

Draft framework and indicators presented to and endorsed by GF-TADs Global Steering Committee (GSC).

Final indicators, reporting tools and piloting process/timeline endorsed by the MC

Piloting of indicators by the GSC and RSCs

Impact/General Objective

**TADs are prevented and progressively controlled**, in order to reduce the threat they pose on animal health, safe trade, food security, and livelihoods worldwide.

Outcome/Specific Objective

**Mechanisms** for TAD prevention, control and response are **effectively implemented** under the GF-TADs umbrella.

Outputs/Deliverabl es

**1.** Improved regional **regulatory frameworks** and coherency of **cross-border strategies** for TAD prevention, control and response.

**2.** Strengthened regional and sub-regional communication and coordination **platforms and networks** for TAD prevention, control & response.

- **3.** Reinforced **veterinary systems** at national, regional and sub-regional levels.
- **4.** Regional and national **investments** in TAD-related prevention, control and response.

Activities/
Resourced actions

International conferences, Round-table meetings, Advocacy work, Resource mobilization efforts, Technical assistance and Expert consultations, Emergency & Assessment Missions, PVS Evaluations, Committee meetings, etc.





#### **Impact/General Objective**



we hope to contribute to this

In attaining the

**Outcome/Specific Objective** 

> we aim to attain this

In delivering the

**Outputs/Deliverabl** es

> we plan to deliver these

In conducting the

**Activities/ Resourced actions** 









# Are we making *progress* on achieving the *results* we said we wanted to achieve?

















"Trial run" to collect data on indicators and test the reporting tools.

Record data sources used (esp. where means of verification are lacking).

Provide feedback and suggestions for improvement to indicators and tools.



### Piloting: coverage

- For Europe: FMD, African Swine fever (ASF), Rabies
- For Africa: FMD, Peste des petits ruminants (PPR), Contagious Bovine Pleuro-Pneumonia (CBPP), ASF, Rift Valley fever (RVF)
- For Asia: FMD, Rabies , PPR
- For Americas: FMD, Classical swine fever (CSF), Rabies ("Main focus on" in the regional action plan)
- For Middle east: FMD, RVF, Brucellosis ("Main focus on" in the regional action plan)







### Piloting: reporting period









#### **GF-TADs KPIs**

#### **21 PERFORMANCE INDICATORS**

Indicator level	Description	Reporting Accountability
Impact and Outcome	Standard internationally- recognized indicators  Data sources = existing FAO/OIE/WHO global databases	GF-TADs Management Committee (MC) and Global Secretariat (GS)
Output	Feasible results of GF-TADS inputs  Most are based on Regional Action Plans.  Some were reported past RSC or GSC meetings.	GF-TADs Regional Steering Committees (RSCs)







#### **Results Statement**

### Performance Indicators (reported by GS)

Impact

TADs are prevented and progressively controlled

**1.** For the priority TADs\* in each region, *number of affected countries.* 




Impact


	Reference	1.1
	Number:	
•	Performance	For each region's priority TADs, the number of affected countries in the
	Indicator:	current year of reporting (and comparison to historical annual data).

FMD

N. of reporting and affected countries (Global)



**FMD** Global % affected countries




#### **Global level**




Impact

Reference	1.1
Number:	
Performance	For each region's priority TADs, the number of affected countries in the
Indicator:	current year of reporting (and comparison to historical annual data).

PPR
N. of reporting and affected countries (Global)



PPR Global % of affected countries







**Impact** 

Reference	1.1
Number:	
Performance	For each region's priority TADs, the number of affected countries in the
Indicator:	current year of reporting (and comparison to historical annual data).

**Rabies** N. of reporting and affected countries (Global)



**Rabies Global** % of affected countries









#### **Results Statement**

## Impact

TADs are prevented and progressively controlled

### Performance Indicators (reported by GS)

**1.** For the priority TADs\* in each region, *number of affected countries.* 

**2.**For the Priority TADs\* in each region, the distribution of countries and zones by *official disease status* for the priority TADs.

#### **Global level**



Impact

Reference	1.2
Number:	
Performance	For the Priority TADs in each region, distribution of countries and zones
Indicator:	by official disease status (and analysis of trends over time, as they move
	through the various stages that are applicable to each disease).

#### FMD: number of countries/zones, by official disease status.

Year	Free countries without Vaccination	Free countries with Vaccination	Free Zone without Vaccination	Free Zone with Vaccination	Countries with endorsed Official Control Programme
2015	67	1	12 (18 zones)	8 (13 zones)	8
2014	66	1	11 (18 zones)	7 (12 zones)	5
2013	66	1	10 (16 zones)	6 (13 zones)	4
2012	65	1	10 (16 zones)	4 (10 zones)	3
2011	65	1	9 (14 zones)	6 (14 zones)	NA
2010	65	1	10	6	NA







ı	4	J
	Ü	5
	1	•
	5	
ı	Ľ	
L		

**Countries with endorsed** 

**Official Control Programme** 

Reference	1.2 (Cont'd.)
Number:	
Performance	For the Priority TADs in each region, distribution of countries and zones
Indicator:	by official disease status (and analysis of trends over time, as they move
	through the various stages that are applicable to each disease).

FMD 2015		
	Country	
Free countries without Vaccination	Albania, Australia, Austria, Belarus, Belgium, Belize, Bosnia and Herzegovina, Brunei, Bulgaria, Canada, Chile, Costa Rica, Croatia, Cuba, Cyprus, Czech Republic, Denmark, Dominican Republic, El Salvador, Estonia, Finland, Former Yug. Rep. of Macedonia, France, Germany, Greece, Guatemala, Guyana, Haiti, Honduras, Hungary, Iceland, Indonesia, Ireland, Italy, Japan, Latvia, Lesotho, Lithuania, Luxembourg, Madagascar, Malta, Mauritius, Mexico, Montenegro, Netherlands, New Caledonia, New Zealand, Nicaragua, Norway, Panama, Philippines, Poland, Portugal, Romania, San Marino, Serbia, Singapore, Slovakia, Slovenia, Spain, Swaziland, Sweden, Switzerland, Ukraine, United Kingdom, United States of America, Vanuatu	
Free countries with Vaccination	Uruguay	
Free Zone without Vaccination	Argentina, Bolivia, Botswana, Brazil, Colombia, Ecuador, Kazakhstan, Malaysia, Moldova, Namibia, Peru, South Africa	
Free Zone with Vaccination	Argentina, Bolivia, Brazil, Colombia, Ecuador, Paraguay, Peru, Turkey	

Algeria, Bolivia, China (People's Rep. of), Ecuador, India, Morocco, Namibia, Venezuela





Impact

Reference Number:	1.2
Performance	For the Priority TADs in each region, distribution of countries and zones
Indicator:	by official disease status (and analysis of trends over time, as they move
	through the various stages that are applicable to each disease).

#### PPR: number of countries/zones, by official disease status.

Year	Free countries	Free Zone	Countries with endorsed Official Control Programme
2015	52	1	0
2014	48	1	0







ı	L	
	į	)
	Ī	•
[	Č	

Reference	1.2 (cont'd)
Number:	
Performance	For the Priority TADs in each region, distribution of countries and zones
Indicator:	by official disease status (and analysis of trends over time, as they move
	through the various stages that are applicable to each disease).

	$\overline{}$	$\overline{}$		$\overline{}$	_	_
D				-		
		156	2			
				W.,		

	Country
Free countries	Argentina, Australia, Austria, Belgium, Bolivia, Bosnia and Herzegovina, Brazil, Canada, Chile, Chinese Taipei, Colombia, Cyprus, Czech Republic, Denmark, Ecuador, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Korea (Rep. of), Liechtenstein, Lithuania, Luxembourg, Malta, Mauritius, Mexico, Myanmar, Netherlands, New Caledonia, New Zealand, Norway, Paraguay, Philippines, Poland, Portugal, Romania, Singapore, Slovakia, Slovenia, South Africa, Spain, Swaziland, Sweden, Switzerland, Thailand, United Kingdom, United States of America
Free Zone	Namibia
Countries with endorsed Official Control Programme	-





#### **Results Statement**

### Performance Indicators (reported by by GS)

Outcome

for TAD prevention, control and response effectively implemented

**1.** Number of *cases reported* of Priority TADs in animals and (where applicable) in humans.

Means of verification: Analysis of data from WAHIS




#### **Global level**



## Outcome

Reference Number: 2.1	
	er of <u>cases</u> reported of Priority TADs in animals and, applicable, in humans.

#### **FMD**






#### **Global level**



Outcome

Reference Number:	2.1
Performance	Number of <u>cases</u> reported of Priority TADs in animals and,
Indicator:	where applicable, in humans.


#### **PPR**



	1	)	)
	٤		
	C	5	)
	Ì		
f	=		
	6		)

Reference Number:	2.1
Performance Indicator:	Number of <u>cases</u> reported of Priority TADs in animals and, where applicable, in humans.

#### Rabies in animals







#### **Results Statement**

### Performance Indicators (reported by GS)

## Outcome

Mechanisms
for TAD
prevention,
control and
response
effectively
implemented


- **1.** Number of *cases reported* of Priority TADs in animals and (where applicable) in humans.
- **2.** Number of *outbreaks* reported of Priority TADs

Means of verification: Analysis of data from WAHIS

## Outcome

Reference Number:	2.2
Performance Indicator:	Number of <u>outbreaks</u> reported of Priority TADs (and, where possible, their spatial distribution).

#### **FMD**






### Outcome

2.2
Number of <u>outbreaks</u> reported of Priority TADs (and, where possible, their spatial distribution).


#### **PPR**



## Outcome

Reference Number:	2.2
	Number of <u>outbreaks</u> reported of Priority TADs (and, where possible, their spatial distribution).

#### Rabies in animals







#### **Results Statement**

#### **Performance Indicators** (reported by by GS)

## Outcome

**Mechanisms** for TAD prevention, control and response effectively implemented

- **1.** Number of *cases reported* of Priority TADs in animals and (where applicable) in humans.
- 2. Number of *outbreaks* reported of **Priority TADs**
- **3.** Proportion (%) of new significant epidemiological events for which countries met *international standards* for immediate notification.

Means of verification: Analysis of data from WAHIS

Reference Number:	2.3
Performance	The proportion (%) of new epidemiological events for
Indicator:	which countries met international standards for
	immediate notification, during the reporting period

Global: immediate notifications in 2014				
Total n. of	N. of	N. of	N. of	N. of
immediate	notifications in	notifications in	notifications in	notifications in
notifications	24 h (%)	72 h (%)	one week (%)	one month (%)
191	65 (34%)	102 (53%)	123 (64%)	167 (87%)





Improved regional regulatory frameworks and coherency of cross-border strategies for TAD prevention, control and response.





#### **Output 1 - Performance Indicators**

Proportion (%) of Regions (or Sub-regions) that have a Regional (or Sub-Regional) Animal Health Strategy.

Proportion (%) of Regions (or Sub-regions) that have a Regional (or Sub-regional) Strategy, Strategic Plan or Road Map for prevention and control of each priority TAD.

For each Region (or Sub-region) that has a Strategy, Strategic Plan or Road Map addressing the priority TADs, proportion (%) of countries in the Region (or Sub-region) that have adopted it.

Proportion (%) of countries in the region/sub-region that have harmonized vaccination strategies for each priority TAD.

Proportion (%) of countries that have adopted a National Contingency Plan for each priority TAD.





Strengthened regional/subregional communication/coordination platforms and networks for TAD prevention, control & response.







#### **Output 2 - Performance Indicators**

- 1. Number of TAD-related **regional or sub-regional coordinating mechanisms** established and active.
- 2. Number of information/knowledge products jointly produced and shared by regional/sub-regional TAD-related coordinating mechanisms during the reporting period
- 3. Proportion (%) of GF-TADs recommendations to date that have been implemented



#### **GF-TADs Output #3:**

Reinforced veterinary systems at regional and sub-regional levels.









#### **Output 3 - Performance Indicators**

- 1. Proportion (%) of regions or sub-regions with an active Lab Network or Veterinary Services Working Group (VSWG).
- 2. Proportion (%) of regions or sub-regions with an <u>active</u> **Epi Network**.
- 3. a) Proportion (%) of Regional Leading/Support Labs **accredited for diagnosis and testing** of the priority TADs. b) Proportion (%) of Regional Leading/Support Labs participating in **proficiency testing** for priority TADs in that region
- 4. Number of national animal health labs that have become **OIE or FAO Reference Centres** or are recognized as a **centre of excellence** (e.g., Regional Leading Lab/Regional Support Lab).

regional

nationa





#### **GF-TADs Output #4:**

Regional and national investments in TAD-related prevention, control and response.







#### **Output 4 - Performance Indicators**

- 1. Number of **TAD-related projects or programmes** secured and currently active, disaggregated by topic, location, donor, etc.
- 2. **Total budget** of such investments (disaggregated by project, donor, and geographic location).